Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > fda max

: 10 mg/d

or 40 mg/d

or N/A (no current medical indication)

Use the filters below to narrow your results.

None (2) · Alprazolam (1) · Amlodipine (1) · Dapagliflozin (1) · Enalapril (and enalaprilat IV) (1) · Ezetimibe (1) · Fluoxetine (1) · Metoclopramide (1) · Nebivolol (1) · Olmesartan (medoxomil) (1) · Phencyclidine (1) · Prazosin (1)

Benicar (1) · Bystolic (1) · Dayvigo (1) · Farxiga (US), Forxiga (international) (1) · Minipress (1) · Norvasc, Katerzia (1) · Prozac (1) · Reglan, Gimoti (intranasal), Metozolv ODT (1) · Sernyl (human, withdrawn 1965); Sernylan (veterinary, withdrawn 1978) (1) · Vasotec, Vasotec IV, Epaned (1) · Viibryd (1) · Xanax (1) · Zetia (1)

None (7) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) · Selective alpha-1 adrenergic receptor antagonist. Lowers peripheral vascular resistance via vasodilation; in the CNS, blunts noradrenergic hyperarousal thought to drive trauma-related nightmares. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · TrkB/BDNF'"`UNIQ--ref-00000047-QINU`"' '"`UNIQ--vote-00000048-QINU`"' (1) · '"`UNIQ--vote-00000073-QINU`"' The long half-life gives smooth, once-daily BP control with low rebound. CYP3A4 substrate; pedal edema is the characteristic, dose-related, non-fluid-overload side effect'"`UNIQ--ref-00000074-QINU`"'. (1)

0.25 mg (1) · 1 mg at bedtime (PTSD nightmares); 1 mg BID–TID (HTN) (1) · 10 mg (1) · 10 mg PO once daily in the morning; 5 mg starting in heart failure (1) · 10 mg PO once daily × 7 days, then 20 mg × 7 days, then 40 mg as target dose (take with food) (1) · 10 mg PO once daily, with or without food (1) · 10 mg PO/IV/IM QID, '''not to exceed 12 weeks''' (tardive dyskinesia risk); intranasal Gimoti 15 mg BID (1) · 2.5-5 mg PO once daily; titrate to 10 mg/d (1) · 20 mg PO once daily; titrate to 40 mg/d after 2 weeks if needed (1) · 5 mg daily (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · 5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) · No current medical indication. Historical anesthetic dose 0.25 mg/kg IV (Sernyl). (1)

0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) · 1, 2, 5 mg caps (1) · 10 mg tablet; also as fixed-dose combinations with simvastatin (Vytorin) and atorvastatin (Liptruzet, withdrawn US 2015 but generics exist) (1) · 10 mg, 20 mg, 40 mg caps (1) · 10 mg, 20 mg, 40 mg tablets (1) · 2.5, 5, 10 mg tablets; 1 mg/mL oral suspension (1) · 2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) · 2.5, 5, 10, 20 mg tabs (1) · 5 mg, 10 mg tablets (2) · 5, 10 mg tablets; 5 mg/5 mL solution; 5 mg/mL IV; 15 mg/spray intranasal (1) · 5, 20, 40 mg tablets (1) · Historical: Sernyl 25 mg tablets, 10 mg/mL injection (human); Sernylan 100 mg/mL injection (veterinary). Illicit: white crystalline powder, oily liquid, "dipped" cigarettes ("wet"), tablets. (1)

IM (2) · insufflated (1) · intranasal (1) · IV (3) · Oral (13) · smoked (1)

None (1) · 1–2 h (1) · 30-60 min (immediate-release); 1-2 h (extended-release) (1) · 30–90 min (1) · 4-6 weeks for full antidepressant effect (claimed earlier onset for some patients due to 5HT1A partial agonism) (1) · BP effect 1 hour; max at 4-6 hours (1) · BP effect 1-2 weeks; max at 2-3 weeks (1) · BP effect within 24 hours; full effect at 1-2 weeks (long half-life) (1) · Glycosuria within hours; HbA1c effect at 12 weeks; CV/renal benefits over months (1) · IV/IM 1-3 minutes; PO 30-60 minutes (1) · LDL lowering within 2 weeks (1) · Smoked 2-5 min; insufflated 5-15 min; oral 30-60 min; IV / IM ~5-15 min (1) · ~30 min (1)

12-24 hours (1) · 24 h (1) · 24 hours (4) · 4-6 hours (1) · 4-8 hours typical; longer at high doses; residual cognitive and perceptual effects up to 48 hours (1) · 6 h (immediate-release); ~11 h (extended-release) (1) · 6–8 h (1) · Daily dosing (1) · Very long (1) · ~7-8 hours (1)

1-3 days acute, 4-6 days chronic; 4-16 days for norfluoxetine'"`UNIQ--ref-0000004C-QINU`"' (1) · 11-13 h (immediate-release); 11-16 h (extended-release) (1) · 2–3 h (1) · 30-50 hours'"`UNIQ--ref-00000078-QINU`"' (1) · 5-6 hours'"`UNIQ--ref-00000EF9-QINU`"' (1) · Highly variable, 7-46 hours (mean ~21 h); lipophilic deposition in fat with delayed re-release contributes to wide range'"`UNIQ--ref-00000065-QINU`"' (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) · ~12.9 hours'"`UNIQ--ref-00000552-QINU`"' (1) · ~13 hours'"`UNIQ--ref-0000056C-QINU`"' (1) · ~17-19 hours (longer than daridorexant) (1) · ~22 hours (parent + active glucuronide)'"`UNIQ--ref-00000450-QINU`"' (1) · ~25 hours (1)

64-90% (oral; not affected by food)'"`UNIQ--ref-00000079-QINU`"' (1) · 70–90% (oral) (1) · 80-90% oral (1) · Variable (oral; rapidly conjugated to active glucuronide; food does not affect)'"`UNIQ--ref-00000451-QINU`"' (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~26% (oral; prodrug hydrolyzed by intestinal esterases to active olmesartan; not affected by food)'"`UNIQ--ref-0000056D-QINU`"' (1) · ~44% (1) · ~60% (1) · ~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1) · ~72% (with food); much lower fasting (~36%) (1) · ~72% oral; ~85% smoked'"`UNIQ--ref-00000066-QINU`"' (1) · ~78% (oral; high-fat meal modestly reduces but is not clinically significant)'"`UNIQ--ref-00000553-QINU`"' (1) · ~80% (oral; reduced by significant first-pass)'"`UNIQ--ref-00000EFA-QINU`"' (1)

None (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection'"`UNIQ--ref-0000056E-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) · Avoid in second and third trimesters; fetal SGLT2 inhibition disrupts kidney development.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Category C (2) · Category C'"`UNIQ--ref-0000004D-QINU`"' (1) · Category D'"`UNIQ--ref-0000006C-QINU`"' (1) · Limited data; avoid (1) · Limited data; case series and registries suggest no major teratogenicity but other antihypertensives (labetalol, nifedipine) are typically preferred.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; generally avoided particularly in combination with statin.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Limited data; weigh benefits/risks (1) · Widely used for hyperemesis gravidarum; reassuring data.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

Rx (1) · Rx, Schedule IV (US) (1) · Rx-only in US (2) · Schedule IV (US) (1) · [[USLegal:DEA Schedule II|Schedule II]] controlled substance in US (rescheduled from Schedule III in 1978). No accepted medical use. UN Convention on Psychotropic Substances Schedule II internationally.'"`UNIQ--ref-00000067-QINU`"' (1) · [[USLegal:Prescription only|Rx-only]] in US (6) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for '''tardive dyskinesia''' (irreversible movement disorder), driving the 12-week chronic-use limit'"`UNIQ--ref-00000EFB-QINU`"' (1)

Showing below up to 13 results in range #1 to #13.

A

D

Dapagliflozin

E

P

V

Vilazodone